Innovation

Cracks through the ice on a melting glacier in Alaska
News

Orphan Drugs Policies: A Suitable Case for Treatment

20 May 2014

Towse and Drummond take a critical look at deficiencies in policy and suggest revisions. An editorial just published by OHE’s Adrian Towse and Michael Drummond of…

The Expanding Value Footprint of Oncology Drugs
News

The Expanding Value Footprint of Oncology Treatments

13 May 2014

A new OHE Consulting Report examines the importance and history of HTA evaluations for additional uses for cancer drugs after their initial approval. The potential value…

Researchers
News

Defining the Complementarity of Medical Research Across Sectors in the UK

11 March 2014

Under an MRC grant, OHE is collaborating to estimate in monetary terms the synergies of medical research spending in the UK by the pharma industry, charities…

Cracks through the ice on a melting glacier in Alaska
News

Benefiting from the Promise of Personalised Medicine: Recent OHE Presentations

18 February 2014

Focusing on England, these two presentations describe the core economic considerations in making the most of targeted therapy. OHE’s Adrian Towse participated in a two-day workshop…

Cracks through the ice on a melting glacier in Alaska
Publication

The Expanding Value Footprint of Oncology Treatments

1 May 2014

This report examines the importance and history of HTA evaluations for additional uses for cancer drugs after their initial approval. Included are the ten cancer drugs approved by the EMA during 2003–2005. Decisions by France’s HAS, NICE and Aetna in the US are analysed.

398 - 2014 Real-Option-Value-Cook-Jul2015
Publication

Real Option Value and Path Dependence in Oncology Innovation

1 April 2014

Based on an OHE Lunchtime Seminar, this publication addresses a persistent issue: how to adequately reward innovation through the pricing of new medicines given the limitations…

Prof Towse on valuing genomic medicines and diagnostics
News

Personalised Medicine and the Value of Molecular Diagnostics: Case Studies

18 December 2013

Progress in personalised medicine is slower than some had expected, partly because of the science and partly because of insufficient economic incentives, particularly for investing in…

Economic Incentives for Evidence Generation: Promoting an Efficient Path to Personalized Medicine
News

Personalised Medicine: Economic Incentives for Evidence Generation

28 October 2013

Four types of economic incentives for drugs and diagnostics are essential to encouraging more rapid progress in personalised medicine. Adrian Towse, OHE’s Director, and Lou Garrison,…

News

Seminar Updates Project on Time Lags in Medical Research

8 October 2013

Progress on this important UK Medical Research Council project was discussed. A major challenge in biomedical and health research is ensuring that research findings are effectively…